Filtered By:
Specialty: Cardiology
Drug: Amiodarone

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 37 results found since Jan 2013.

Cost-effectiveness analysis of dronedarone versus amiodarone, propafenone and sotalol in patients with atrial fibrillation: results for Serbia.
CONCLUSIONS: Results of our model indicate that dronedarone is cost effective therapy compared with amiodarone, propafenone and sotalol in patients with atrial fibrillation if the outcome is number of years spent without stroke. PMID: 25428811 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - November 27, 2014 Category: Cardiology Authors: Tesic D, Kostic M, Paunovic D, M Jankovic S Tags: Kardiol Pol Source Type: research

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
Conclusions: Allowing for differences in prescribing practice, AF/AFL patients treated with W+A are at higher risk of stroke and arterial embolism, and have higher healthcare use and costs, than patients receiving W+OAAD.
Source: International Journal of Cardiology - February 15, 2012 Category: Cardiology Authors: Annie Guérin, Jay Lin, Mehul Jhaveri, Eric Q. Wu, Andrew P. Yu, Martin Cloutier, Genevieve Gauthier, Joseph S. Alpert Tags: Original Articles Source Type: research

Abstract 151: Outcomes Associated With Prophylactic Amiodarone Protocol in Patients Undergoing Cardiac Surgery: A Single Center Experience Session Title: Poster Session I
Conclusions: Implementation of an amiodarone prophylaxis protocol order care set was associated with greater utilization of amiodarone. It was also associated with a modest decrease in the incidence of STS-defined POAF, stroke and MI but was not associated with a change in 30-day mortality in patients undergoing cardiac surgery. Further studies are needed to study the cost-effectiveness and risk-benefit analysis of routine amiodarone as prophylaxis.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Atreya, A. R., Arora, S., Garb, J., Rousou, J., Lindenauer, P., Lotfi, A. Tags: Session Title: Poster Session I Source Type: research

Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin　- Insights From the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: HDE had a greater relative efficacy and safety in EA compared with Japan that was only partially explained by differences in baseline characteristics and TTR. PMID: 26460886 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 9, 2015 Category: Cardiology Authors: Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, Mercuri M, Ruff CT, Giugliano RP Tags: Circ J Source Type: research

Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis
ConclusionThe benefit-risk profile of NOACs compared to VKAs was preserved in AF patients using P-gp/CYP3A4 inhibitors, including amiodarone.
Source: Cardiovascular Drugs and Therapy - October 12, 2021 Category: Cardiology Source Type: research

Risk of Atrial Fibrillation after Atrial Flutter Ablation: Impact of AF History, Gender and Antiarrhythmic Drug Medication
ConclusionsAF occurrence after AFL ablation is frequent (>20%), especially in patients with a history of AF, in female patients, and in patients treated with Class I antiarrythmics/Amiodarone prior to AFL. Since most patients who experience AF after AFL ablation have a CHA2DS2‐VASc≥1, the decision to stop anticoagulants after ablation should be considered on an individual basis.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - March 21, 2014 Category: Cardiology Authors: BÉATRICE BREMBILLA‐PERROT, NICOLAS GIRERD, JEAN MARC SELLAL, ARNAUD OLIVIER, VLADIMIR MANENTI, THIBAUT VILLEMIN, DANIEL BEURRIER, CHRISTIAN DE CHILLOU, PIERRE LOUIS, OLIVIER SELTON, ARNAUD TERRIER DE LA CHAISE Tags: Original Article Source Type: research

Risk of Atrial Fibrillation After Atrial Flutter Ablation: Impact of AF History, Gender, and Antiarrhythmic Drug Medication
ConclusionsAF occurrence after AFL ablation is frequent (>20%), especially in patients with a history of AF, in female patients, and in patients treated with class I antiarrythmics/amiodarone prior to AFL. Since most patients who experience AF after AFL ablation have a CHA2DS2‐VASc ≥1, the decision to stop anticoagulants after ablation should be considered on an individual basis.
Source: Journal of Cardiovascular Electrophysiology - April 21, 2014 Category: Cardiology Authors: BÉATRICE BREMBILLA‐PERROT, NICOLAS GIRERD, JEAN MARC SELLAL, ARNAUD OLIVIER, VLADIMIR MANENTI, THIBAUT VILLEMIN, DANIEL BEURRIER, CHRISTIAN CHILLOU, PIERRE LOUIS, OLIVIER SELTON, ARNAUD TERRIER CHAISE Tags: Original Article Source Type: research

Abstract 374: Quality Improvement Program to Optimize Pre-Operative Evaluation of Elective Cardiovascular Surgery Patients Reduces Complications and Improves Length of Stay Session Title: Poster Session III
Conclusions: A standardized pre-operative evaluation protocol in combination with prophylactic amiodarone in appropriate patients was associated with lower overall complications and a reduction in post-operative AF and LOS. Standardized protocols may enable health care providers to optimize pre-operative management of elective surgery patients and improve care quality and outcomes.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Porten, B. R., Strauss, C. E., Mueller, J. J., Garberich, R. F., Sun, B. C., Abdelhadi, R. H., Henry, T. D. Tags: Session Title: Poster Session III Source Type: research

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research

Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Conclusions -Transient symptomatic episodes of AF, although relatively uncommon in HCM, are unpredictable in frequency and timing, amenable to effective contemporary treatments, and infrequently progress to permanent AF. AF is not a major contributor to heart failure morbidity, nor a cause of arrhythmic sudden death, and when treated is associated with low-disease-related mortality, no different than for patients without AF. AF is an uncommon primary cause of death in HCM virtually limited to embolic stroke, supporting a low threshold for initiating anticoagulation therapy. PMID: 28916640 [PubMed - as supplied by publisher]
Source: Circulation - September 15, 2017 Category: Cardiology Authors: Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ Tags: Circulation Source Type: research

Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin
ConclusionAmong patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin.
Source: Journal of Interventional Cardiac Electrophysiology - August 20, 2018 Category: Cardiology Source Type: research

Apples will never be oranges, but when you go fishing you may get a bite
Dronedarone is the newest available oral antiarrhythmic drug (AAD). In a paper by Ehrlich et al. [1] accompanying this editorial the authors report on risks for myocardial infarction (MI) and stroke in AF patients given a first prescription for dronedarone, amiodarone, flecainide, propafenone, or sotalol in 1258 general and 62 cardiology practices between January 2010 and March 2017. They attempt to compare MI and stroke risks in dronedarone patients (n  = 3498) versus those treated with all the other stated antiarrhythmic drugs (AAD) analyzed in combination (n = 17,724).
Source: International Journal of Cardiology - December 13, 2018 Category: Cardiology Authors: James A. Reiffel Tags: Editorial Source Type: research

Patterns of Amiodarone use and outcomes in clinical practice for atrial fibrillation
ConclusionsUse of amiodarone among AF patients in community practice is highly variable. More than 2 out of 3 patients treated with amiodarone appeared to be eligible for a different AAD.
Source: American Heart Journal - October 24, 2019 Category: Cardiology Source Type: research

Temporal changes in patient characteristics and prior pharmacotherapy in patients undergoing radiofrequency ablation of atrial fibrillation: a Danish nationwide cohort study
Conclusion During a 10-year period, RFA was increasingly performed in older patients with higher co-morbidity, and without prior trial of antiarrhythmic therapy. These findings may provide a framework to understand the outcomes of RFA.
Source: Europace - April 26, 2013 Category: Cardiology Authors: Karasoy, D., Gislason, G. H., Hansen, J., Olesen, J. B., Torp-Pedersen, C., Johannessen, A., Hansen, M. L. Tags: Ablation for atrial fibrillation Source Type: research